TSTickerStarGet alerts

QCLS 10-Q filed 2026-11-16 | Key takeaways

QCLS filed its 10-Q; the most relevant disclosure change is added Subsequent events - Nasdaq deficiency notice: On November 6, 2026, the Company received a written notice from Nasdaq stating that the Company no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company has unt.

Share this story

Key takeaways

  • Nasdaq deficiency notice: Company received notice on November 6, 2026 that it no longer meets the $1.00 minimum bid price requirement; has until May 5, 2027 to regain compliance.

  • LightSolver license termination: On June 26, 2026, company provided notice to terminate the Technology License Agreement with LightSolver, relieving obligation for additional milestone payments and eliminating contingent consideration.

  • PharmaCyte warrant exchange: On November 15, 2026, company entered into agreement to exchange 851,304 Series G Long-Term Warrants for 4,982,272 shares of Common Stock, and extended Series H Preferred Stock maturity from March 2, 2027 to September 2, 2027.

  • Stock-based compensation correction: Company identified errors in accounting for stock-based compensation in Q1 and Q2 2026, revising previously reported interim financial information; deemed immaterial to prior periods.

  • Working capital position: Company reported working capital of $8.18 million and stockholders' equity of $16.12 million as of September 30, 2026, with cash of $2.59 million and marketable securities of $6.81 million.

Key metrics

Net loss (Q3 2026)Q3 2026
$941,793N/A - company is pre-revenue
Net loss (9M 2026)Nine months ended September 30, 2026
$11,313,780$5.58M increase in net loss vs prior year
Net loss attributable to common stockholders (Q3 2026)Q3 2026
$1,206,036N/A
Net loss attributable to common stockholders (9M 2026)Nine months ended September 30, 2026
$11,786,978$3.36M increase vs prior year
Basic and diluted net loss per common share (Q3 2026)Q3 2026
$(0.14)N/A
Basic and diluted net loss per common share (9M 2026)Nine months ended September 30, 2026
$(1.42)N/A
Cash used in operating activities (9M 2026)Nine months ended September 30, 2026
$6,640,396$774K increase in cash used
Cash and cash equivalentsSeptember 30, 2026
$2,585,051

Disclosure changes

  • Subsequent events - Nasdaq deficiency notice

    On November 6, 2026, the Company received a written notice from Nasdaq stating that the Company no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company has until May 5, 2027 to regain compliance.

    Risk of delisting could trigger redemption and other rights under outstanding preferred stock and adversely affect liquidity and price of Common Stock.
  • Subsequent events - PharmaCyte warrant exchange

    On November 15, 2026, the Company entered into a Consent and Warrant Exchange Agreement with PharmaCyte Biotech, Inc., a related party. PharmaCyte agreed to exchange 851,304 Series G Long-Term Warrants for an aggregate of 4,982,272 shares of Common Stock, determined based on Black Scholes value divided by $0.3101 per share. PharmaCyte also consented to a six-month extension of the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027.

    Dilutive transaction with related party extending preferred stock maturity; significant dilution at current stock price.
  • Technology license impairment

    On June 26, 2026, the Company provided notice of its intention to terminate the Technology License and Development Agreement with LightSolver, effective June 26, 2026. In connection with the Termination, the Company was automatically relieved from its obligation to make any additional milestone payments, and LightSolver has no right to receive any further contingent consideration. The Company recorded an impairment charge of $3,177,999 with respect to the Exclusive License for the nine months ended September 30,...

    Full impairment of LightSolver technology license eliminates future milestone payment obligations but represents write-off of significant intangible asset.
  • Stock-based compensation correction

    In connection with preparation of Q3 2026 financial statements, the Company identified errors in accounting for certain stock-based compensation awards that resulted in understatement of stock-based compensation expense, additional paid-in capital, and accumulated deficit in previously issued Q1 and Q2 2026 Quarterly Reports. The error was evaluated and concluded not material to any previously issued financial statements. The revision did not affect cash, total assets, total liabilities, revenues, or cash flows.

    Correction of prior period errors affects comparability of stock-based compensation expense across quarters.
  • Contingent consideration payable

    Contingent Consideration Payable was reduced to $0 as of September 30, 2026, down from $10,909,000 at December 31, 2025. This was due to the termination of the LightSolver Licensing Agreement which eliminated the contingent consideration obligation.

    Elimination of contingent consideration liability improves balance sheet but was driven by license termination rather than payment.
  • Derivative liability

    Derivative Liability decreased to $25,000 as of September 30, 2026, down from $2,157,000 at December 31, 2025, primarily due to changes in fair value.

    Significant reduction in derivative liability reflects fair value changes and conversion of preferred stock.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow QCLS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert